Author:
Ostios-Garcia Lorena,Pérez Daniel Martínez,Castelo Beatriz,Herradón Noelia Hernández,Zamora Pilar,Feliu Jaime,Espinosa Enrique
Abstract
AbstractAnticancer systemic therapy comprises a complex and growing group of drugs. Some of the new agents with novel mechanisms of action that have appeared are difficult to fit in the groups of classical chemotherapy, hormones, tyrosine-kinase inhibitors, and monoclonal antibodies. We propose a classification based on two levels of information: the site of action and the mechanism of action. Regarding the former, drugs can exert their action in the tumor cell, the tumor vasculature, the immune system, or the endocrine system. The mechanism of action refers to the molecular target.
Funder
Universidad Autónoma de Madrid
Publisher
Springer Science and Business Media LLC
Reference54 articles.
1. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68, 394–424. https://doi.org/10.3322/caac.21492
2. Goodman, L. S., Wintrobe, M. M., Dameshek, W., Goodman, M. J., Gilman, A., & McLennan, M. T. (1946). Landmark article Sept. 21, 1946: Nitrogen mustard therapy. Use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin’s disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. By Louis S. Goodman, Maxwell M. Wintrobe, William Dameshek, Morton J. Goodman, Alfred Gilman and Margaret T. McLennan. JAMA, 1984(251), 2255–2261. https://doi.org/10.1001/jama.251.17.2255
3. DeVita, V. T, Lawrence, T., & Rosenberg, S.A. (2022). DeVita, Hellman, and Rosenberg’s cancer: Principles & practice of oncology. Part III: Cancer therapeutics (12th ed., pp. 218–386). WOLTERS KLUWER.
4. O’Leary, B., Finn, R. S., & Turner, N. C. (2016). Treating cancer with selective CDK4/6 inhibitors. Nature Reviews Clinical Oncology, 13, 417–430. https://doi.org/10.1038/nrclinonc.2016.26
5. Rose, M., Burgess, J. T., O’Byrne, K., Richard, D. J., & Bolderson, E. (2020). PARP inhibitors: Clinical relevance, mechanisms of action and tumor resistance. Frontiers in Cell and Developmental Biology, 8, 564601. https://doi.org/10.3389/fcell.2020.564601
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献